Anti-VEGF for age-related macular degeneration

2025 05 02 Owen Yang

Anti-VEGF ocular injection, under the drug group Ophthalmological anti-neovascularisation agents (#S01L) in Prescribing in Taiwan, has been funded under the Taiwan National Health Insurance for age-related macular degenetation since 2011. It is important to be aware that only up to 14 doses in a lifetime can be funded for each eye, equivalent to approximately 2 years of treatment. Treatment beyond this, if needed, is not funded and therefore unlikely to be recorded.
Anti-VEGF ocular injection can also be used in other diseases such as diabetic macular oedema. Note that similar anti-VEGF (Bevacizumab) has also been used as an anti-neoplastic agent with ATC code #L01FG under a different drug group Antineoplastic agents, Monoclonal antibodies and antibody drug conjugates (#L01F)